logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Ascletis Pharma-B (01672.HK) repurchased 200,000 shares for HK$1.2215 million on October 14.

date
14/10/2026
Zhitong Finance APP News, Ascletis Pharma-B (01672.HK) announced that the company repurchased 200,000 shares on October 14, 2026, for HK$1.2215 million, at a repurchase price of HK$5.88-6.715 per share.
Latest
1 m ago
M&G Plc increases its shareholding in Crystal International (02232) by 445,000 shares at approximately HK$7.06 per share.
1 m ago
Morgan Stanley increased its holdings in Cambridge Technology (06166) by approximately 5.1428 million shares at a price of approximately HK$105.69 per share.
3 m ago
Abbisko-B (02256.HK) repurchased 50,000 shares for HK$371,900 on October 14.
5 m ago
China Merchants Securities (06099.HK): Public issuance of short-term corporate bonds to professional investors receives registration approval from the China Securities Regulatory Commission
5 m ago
Qiaoyin Co., Ltd.: Qiaoyin Convertible Bonds Are About to Mature and Trading Will Cease
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.